Tenderwize
Retour à la recherche

Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cabotegravir in der Darreichungsform Depot-Injektionssuspension, ATC J05AJ04

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or guaranteed purchase volume; participation may not yield significant business.

Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of non-exclusive discount agreements for Cabotegravir (ATC J05AJ04) in depot injection suspension form.
  • Agreements are identical for all participants and not individually negotiable.
Afficher le résumé complet

AOK Bayern is offering non-exclusive discount agreements under an open-house model for the pharmaceutical product Cabotegravir (ATC J05AJ04, depot injection suspension) to all interested pharmaceutical companies that meet eligibility criteria. The contract runs from June 2026 to May 2028, with possible termination under certain conditions. This is not a standard procurement procedure; participation is open, but no estimated value is provided.

Risques

No estimated value or guaranteed purchase volume; participation may not yield significant business.

Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible.

Administrative

  • Submission of a signed self-declaration of reliability, signed contract, and filled annex on medicinal products.
  • Documents must be submitted either in paper form (two original copies) or electronically with a qualified electronic signature.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)

Single lot covering all agreements for Cabotegravir. The open-house model allows any eligible pharmaceutical company to conclude identical, non-negotiable discount agreements. The contract period is from 01.06.2026 to 31.05.2028, with rolling monthly cutoff for document submission.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
257297-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30